Want to see FR:TNG full AI Analyst Report?
TNG Stock Chart & Stats
€0.72
>-€0.01(-0.41%)
At close: 4:00 PM EDT
€0.72
>-€0.01(-0.41%)
Day’s Range― - ―
52-Week Range€0.71 - €1.50
Previous CloseN/A
Volume24.07K
Average Volume (3M)129.86K
Market Cap
€197.86M
Enterprise Value€103.55M
Total Cash (Recent Filing)€111.86M
Total Debt (Recent Filing)€2.06M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding278,559,940
10 Day Avg. Volume204,663
30 Day Avg. Volume129,863
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)282.76
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€8.15M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseVery low financial leverage and a sizable equity base give Transgene structural balance-sheet flexibility versus peers. That reduces immediate solvency risk, supports continued R&D spending without high interest burdens, and provides optionality for strategic funding choices over months.
Partnership-driven Business ModelA partnership and collaboration model aligns capital and development risk with external parties, creating recurring non-product revenue streams (upfront, milestones, research funding). Over time this diversifies funding sources and accelerates development without sole reliance on product sales.
Prior Revenue Growth And Improving FCF TrendHistorical revenue expansion and a measurable improvement in free cash flow indicate the company can scale collaboration income and modestly reduce cash burn. Sustained improvement in cash conversion would lengthen runway and lower near-term financing dependence if trends continue.
Bears Say
Persistent Operating LossesOngoing operating and net losses reflect a cost base driven by R&D and clinical programs that is not covered by current revenue. Over a multi-month horizon this necessitates repeated external funding, creates dilution risk for shareholders, and limits internal investment flexibility.
Severe Revenue Collapse In 2025A near-total revenue decline makes top-line income highly lumpy and unreliable. This volatility undermines ability to fund fixed R&D costs from operations, complicates multi-quarter planning, and increases dependence on milestone or financing events for sustaining development programs.
Negative Margins And Cash Burn MagnitudeExtremely negative margins and substantial negative operating/ free cash flow show that losses translate into real cash consumption. Without clinical success or material partner payments, this structural cash burn shortens runway and forces dilution or constrained program choices over the medium term.
Transgene News
TNG FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.71 and its highest was €1.50 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €197.86M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Sep 24, 2026 which is in 50 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 278,559,940 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in FR:TNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―